Posted by Michael Wonder on 20 Dec 2018
Dengvaxia vaccine approved for prevention of dengue in Europe
19 December 2018 - The European Commission has granted marketing authorization for Dengvaxia®, Sanofi’s dengue vaccine.
The marketing authorization follows the 18 October 2018, recommendation by the European Medicines Agency’s CHMP to approve use of the dengue vaccine in European endemic areas.
Dengvaxia will be available in Europe to prevent dengue disease in individuals 9-45 years of age with a documented prior dengue infection and who are living in endemic areas.
